Drugs / HER2-E-CART cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05745454 | Feb → Dec 2023 | cancer | suhaichuan | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HER2-E-CART cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05745454 ↗ |
| Known as | E-CAR-T | “E-CAR-T is a novel second-generation CAR-T product targeting HER2 protein” NCT05745454 ↗ |
| Modality | Cell therapy | “novel second-generation CAR-T product” NCT05745454 ↗ |
| Route | Intravenous | “given intravenous infusion” NCT05745454 ↗ |